financetom
Business
financetom
/
Business
/
Goldman Sachs faces US CFPB fine over credit card business, WSJ reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman Sachs faces US CFPB fine over credit card business, WSJ reports
Oct 22, 2024 12:41 PM

(Reuters) -Goldman Sachs ( GS ) is facing a fine in the tens of millions of dollars from the U.S. Consumer Financial Protection Bureau over its credit card business, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

The consumer watchdog's enforcement action is tied to an investigation into Goldman's customer service operations with a focus on the Apple credit card partnership, the report said.

The enforcement action is expected to come this week, the report said, adding that the total penalties including customer reimbursements could be over $50 million.

Goldman Sachs ( GS ) and the CFPB declined to comment on the report.

In 2022, Goldman had disclosed that its credit card business was being investigated by the CFPB and other government bodies.

The investigations included scrutiny of the bank's credit card management practices, refunds and billing error resolution, the bank had said at the time.

The fine would come as Goldman continues to struggle exiting its ill-fated consumer business two years after stepping back from it.

Goldman's card partnership with Apple is also facing an uncertain future, with Wall Street titan JPMorgan in talks to replace the bank as the tech giant's credit card partner, Reuters had reported.

The bank recently exited its credit card partnership with automaker General Motors, which earlier this month struck a deal with Barclays.

Last week, Goldman booked a $415 million hit that included a writedown related to the transfer of the credit business to Barclays.

The writedown was the latest in a string of losses from Goldman's consumer banking foray, which had aimed to broaden the bank's revenue beyond its traditional mainstays of investment banking and trading.

The bank has since shifted its focus onto its traditional mainstays.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
--FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports
--FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports
Apr 8, 2025
10:45 AM EDT, 04/08/2025 (MT Newswires) -- Price: 61.92, Change: +3.07, Percent Change: +5.22 ...
Rio Tinto hopes Trump provides favorable path for Resolution copper mine
Rio Tinto hopes Trump provides favorable path for Resolution copper mine
Apr 8, 2025
SANTIAGO, April 8 (Reuters) - Miner Rio Tinto sees U.S. President Donald Trump's administration showing more interest in a bigger copper supply chain and hopes that will help push forward its Resolution mine project in Arizona, Rio's copper CEO Katie Jackson said on Tuesday. We hope that will be part of getting projects like Resolution to move, she told the...
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Apr 8, 2025
Pacira BioSciences, Inc ( PCRX ). on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine liposome injectable suspension). Exparel is Pacira BioSciences' ( PCRX ) non-opioid analgesic pain management and is indicated for postsurgical analgesia. As part of the settlement, the parties will file...
Copyright 2023-2026 - www.financetom.com All Rights Reserved